Literature DB >> 23240746

Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors.

Jaina Patel1, Erica N Bozeman, Periasamy Selvaraj.   

Abstract

Evaluation of: Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842 (2012). The identification of TIM-3 expression on tumor-associated dendritic cells (TADCs) provides insight into another aspect of tumor-mediated immunosuppression. The role of TIM-3 has been well characterized on tumor-infiltrating T cells; however, its role on TADCs was not previously known. The current paper demonstrated that TIM-3 was predominantly expressed by TADCs and its interaction with the nuclear protein HMGB1 suppressed nucleic acid-mediated activation of an effective antitumor immune response. The authors were able to show that TIM-3 interaction with HMGB1 prevented the localization of nucleic acids into endosomal vesicles. Furthermore, chemotherapy was found to be more effective in anti-TIM-3 monoclonal antibody-treated mice or mice depleted of all DCs, which indicated that a significant role is played by TADCs in inhibiting tumor regression. Taken together, these findings identify TIM-3 as a potential target for inducing antitumor immunity in conjunction with DNA vaccines and/or immunogenic chemotherapy in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23240746      PMCID: PMC4020625          DOI: 10.2217/imt.12.126

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  11 in total

Review 1.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

2.  Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.

Authors:  Ana C Anderson; David E Anderson; Lisa Bregoli; William D Hastings; Nasim Kassam; Charles Lei; Rucha Chandwaskar; Jozsef Karman; Ee W Su; Mitsuomi Hirashima; Jeffrey N Bruce; Lawrence P Kane; Vijay K Kuchroo; David A Hafler
Journal:  Science       Date:  2007-11-16       Impact factor: 47.728

3.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 4.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

6.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model.

Authors:  Enrico Proietti; Laura Bracci; Simona Puzelli; Tiziana Di Pucchio; Paola Sestili; Enrico De Vincenzi; Massimo Venditti; Imerio Capone; Isabelle Seif; Edward De Maeyer; David Tough; Isabella Donatelli; Filippo Belardelli
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

8.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  TIMs: central regulators of immune responses.

Authors:  David A Hafler; Vijay Kuchroo
Journal:  J Exp Med       Date:  2008-11-17       Impact factor: 14.307

10.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Authors:  R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski
Journal:  J Exp Med       Date:  2008-11-10       Impact factor: 14.307

View more
  21 in total

Review 1.  Role of Tim-3 in hepatitis B virus infection: An overview.

Authors:  Yuan Liu; Li-Fen Gao; Xiao-Hong Liang; Chun-Hong Ma
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.

Authors:  Yuanxing Liu; Haofeng Ji; Yu Zhang; Xiuda Shen; Feng Gao; Xiangyi He; Gabriella A Li; Ronald W Busuttil; Vijay K Kuchroo; Jerzy W Kupiec-Weglinski
Journal:  J Hepatol       Date:  2014-10-31       Impact factor: 25.083

Review 3.  Role of TIM-3 in ovarian cancer.

Authors:  Y Xu; H Zhang; Y Huang; X Rui; F Zheng
Journal:  Clin Transl Oncol       Date:  2017-03-29       Impact factor: 3.405

4.  Negative regulation of Nod-like receptor protein 3 inflammasome activation by T cell Ig mucin-3 protects against peritonitis.

Authors:  Wei Wang; Qingzhu Shi; Shuaijie Dou; Ge Li; Xinhui Shi; Xingwei Jiang; Zhiding Wang; Dandan Yu; Guojiang Chen; Renxi Wang; He Xiao; Chunmei Hou; Jiannan Feng; Beifen Shen; Yuanfang Ma; Gencheng Han
Journal:  Immunology       Date:  2017-09-18       Impact factor: 7.397

5.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

6.  Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.

Authors:  Prathyusha Konda; John A Roque Iii; Liubov M Lifshits; Angelita Alcos; Eissa Azzam; Ge Shi; Colin G Cameron; Sherri A McFarland; Shashi Gujar
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

Review 7.  Tipping the balance: inhibitory checkpoints in intestinal homeostasis.

Authors:  Maria E Joosse; Iris Nederlof; Lucy S K Walker; Janneke N Samsom
Journal:  Mucosal Immunol       Date:  2018-11-29       Impact factor: 7.313

Review 8.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

9.  Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells.

Authors:  Sudipta Tripathi; Lola Chabtini; Pranal J Dakle; Brian Smith; Hisaya Akiba; Hideo Yagita; Indira Guleria
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

10.  Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer.

Authors:  S H Petersen; L F Kua; S Nakajima; W P Yong; K Kono
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.